REGENERON PHARMACEUTICALS, INC. (REGN) FY2026 Q1 Balance Sheet

Income StatementCash FlowBalance Sheet

Balance Sheet

As of 2026-03-31

Swipe to see the full flow
REGENERON PHARMACEUTICALS, INC. (REGN) FY2026 Q1 Balance SheetBalance sheet as of 2026-03-31. The chart shows assets, liabilities and equity at that date.Current liabilities$5.11 BLiabilities$9.45 BCurrent assets$18.21 BNon-current liabilities$4.34 BAssets$40.87 BEquity$31.42 BGross equity(calculated)$50.84 BNon-current assets$22.66 BHOLDINGSASSET CLASSASSETSCLAIM CLASSCLAIM SUB-CLASSCLAIMSMarketable securitiesAccounts receivable, netInventoriesCash and cash equivalentsPrepaid expenses and other current assetsMarketable securitiesProperty, plant, and equipment, netDeferred tax assetsOther noncurrent assetsIntangible assets, netAccrued expenses and other current liabilitiesAccounts payableFinance lease liabilitiesDeferred revenueOther noncurrent liabilitiesLong-term debtDeferred revenueRetained earningsAdditional paid-in capitalAccumulated other comprehensive incomeCommon stock - Common StockCurrent assetsNon-current assetsAssetsCurrent liabilitiesNon-current liabilitiesLiabilitiesEquityGross equity (calculated)Treasury Stock, at cost; 34.7 shares in 2026 and 33.7 shares in 2025Accrued expenses and other current liabilitiesAccrued expenses and other current liabilities$2.72 BCurrent liabilitiesCurrent liabilities$5.11 BAccounts payableAccounts payable$1.03 BLiabilitiesLiabilities$9.45 BFinance lease liabilitiesFinance lease liabilities$720.00 MDeferred revenueDeferred revenue$636.20 MCurrent assetsCurrent assets$18.21 BMarketable securitiesMarketable securities$5.79 BNon-current liabilitiesNon-current liabilities$4.34 BOther noncurrent liabilitiesOther noncurrent liabilities$2.13 BAssetsAssets$40.87 BAccounts receivable, netAccounts receivable, net$5.73 BLong-term debtLong-term debt$1.99 BEquityEquity$31.42 BInventoriesInventories$3.10 BDeferred revenueDeferred revenue$225.10 MCash and cash equivalentsCash and cash equivalents$2.96 BGross equity (calculated)Gross equity(calculated)$50.84 BPrepaid expenses and other current assetsPrepaid expenses and other current assets$620.90 MNon-current assetsNon-current assets$22.66 BMarketable securitiesMarketable securities$9.79 BRetained earningsRetained earnings$36.42 BProperty, plant, and equipment, netProperty, plant, and equipment, net$5.27 BDeferred tax assetsDeferred tax assets$4.19 BOther noncurrent assetsOther noncurrent assets$2.13 BIntangible assets, netIntangible assets, net$1.29 BAdditional paid-in capitalAdditional paid-in capital$14.40 BAccumulated other comprehensive incomeAccumulated other comprehensive income$11.90 MCommon stock - Common StockCommon stock - Common Stock$100.00 KTreasury Stock, at cost; 34.7 shares in 2026 and 33.7 shares in 2025Treasury Stock−$19.41 B
Chart details

REGENERON PHARMACEUTICALS, INC. (REGN) FY2026 Q1 Balance Sheet

Balance sheet as of 2026-03-31. The chart shows assets, liabilities and equity at that date.

Assets
40,868,800,000 US dollars
Current assets
18,209,200,000 US dollars
Non-current assets
22,659,600,000 US dollars
Liabilities
9,445,200,000 US dollars
Current liabilities
5,107,700,000 US dollars
Non-current liabilities
4,337,500,000 US dollars
Equity
31,423,600,000 US dollars
Marketable securities
5,791,100,000 US dollars
Accounts receivable, net
5,731,000,000 US dollars
Inventories
3,103,600,000 US dollars
Cash and cash equivalents
2,962,600,000 US dollars
Prepaid expenses and other current assets
620,900,000 US dollars
Marketable securities
9,786,000,000 US dollars
Property, plant, and equipment, net
5,266,100,000 US dollars
Deferred tax assets
4,190,900,000 US dollars
Other noncurrent assets
2,129,700,000 US dollars
Intangible assets, net
1,286,900,000 US dollars
Accrued expenses and other current liabilities
2,724,400,000 US dollars
Accounts payable
1,027,100,000 US dollars
Finance lease liabilities
720,000,000 US dollars
Deferred revenue
636,200,000 US dollars
Other noncurrent liabilities
2,126,200,000 US dollars
Long-term debt
1,986,200,000 US dollars
Deferred revenue
225,100,000 US dollars
Finance lease liabilities
0 US dollars
Retained earnings
36,423,800,000 US dollars
Additional paid-in capital
14,401,300,000 US dollars
Accumulated other comprehensive income
11,900,000 US dollars
Common stock - Common Stock
100,000 US dollars
Common stock - Class A Stock
0 US dollars
Preferred Stock, par value $.01 per share; 30.0 shares authorized; shares issued and outstanding - none
0 US dollars
Treasury Stock, at cost; 34.7 shares in 2026 and 33.7 shares in 2025
negative 19,413,500,000 US dollars
Gross equity (calculated)
50,837,100,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

Chart connections

  • Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
  • Treasury shares and other negative equity contributions reduce equity.
REGENERON PHARMACEUTICALS, INC. (REGN) FY2026 Q1 Balance Sheet Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!